Abstract:CDK4/6 inhibitors have proven effective in treating HR+/HER2- breast cancer, but their limited therapeutic indications and the emergence of acquired resistance are concerning. Recent studies suggest that hematological toxicity linked to CDK4/6 dual inhibitors may be due to strong CDK6 inhibition. To address these challenges, small molecules targeting different CDK subfamily members could provide clinical advantages in specific patient subgroups and expand CDK inhibitor indications beyond breast cancer. However, the high conservation of CDK's binding pocket makes designing molecules selectively targeting different CDKs challenging. In this study, we use in-depth in silico modeling and structural biology analysis of co-crystal data to analyze subtle variations in several CDKs' key binding pockets. Our findings indicate that a sequential difference of a αD-helix motif between CDK4 and CDK6 represents an ideal "sweet spot" that influences binding selectivity. To achieve this selectivity, we designed small molecules with a 1,4-trans-cyclohexanediamine sidechain that specifically promotes interactions with the αD-helix motif in CDK4 but not in CDK6. Interestingly, the same αD-helix motif in CDK9 presented an opportunity to develop a CDK4/9 inhibitor, potentially improving acquired resistance to CDK4/6 inhibitors. Our rational approach identified a series of analogs exhibiting distinct in vitro selectivity among CDK4, CDK6, and CDK9. The lead compound (29) was further evaluated for in vivo pharmacokinetics. This work revealed key molecular insights for developing next-generation CDK inhibitors with unique selectivity profiles. This approach could help overcome the challenges of developing selective CDK inhibitors and broaden their therapeutic indications beyond breast cancer.

Design, Synthesis and Anticancer Evaluation of Selective 2,4-Disubstituted Pyrimidine CDK9 Inhibitors

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities

Design, Synthesis and Biological Evaluation of Pteridine-7(8H)-one Derivatives As Potent and Selective CDK4/6 Inhibitors

Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors

Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors

Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors

Design, synthesis, molecular modeling and evaluation of 2,4-diaminopyrimidine analogues as promising colorectal cancer drugs

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors

Design, synthesis, and biological evaluation of (E)-N′-substitute-4-((4-pyridylpyrimidin-2-yl)amino)benzohydrazide derivatives as novel potential CDK9 inhibitors

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

Discovery and optimization of thieno[3,2- d ]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7

Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.

Novel purine derivatives as selective CDK2 inhibitors with potential anticancer activities: Design, synthesis and biological evaluation

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.

Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2h-pyran-4-carbonitrile (JSH-150) As a Novel Highly Selective and Potent CDK9 Kinase Inhibitor.

Design, synthesis and biological assessment of novel CDK4 inhibitor with potent anticancer activity

Discovery of novel pyrrolo[2,3-d]pyrimidine derivatives as anticancer agents: virtual screening and molecular dynamic studies

Elucidating Binding Selectivity in Cyclin-Dependent Kinases (CDKs) 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors